News Sentiment

INDP sentiment intelligence

Indaptus Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 46 Balanced news tone 45 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 2.53 Week of 17 Jul 2026
Weighted tone 46/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

76/100 classification confidence.

Company focus 36

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend active

-3.8% over one week, -35.1% over four weeks, trend active, and below fair value.

Latest direct headline Neutral

Indaptus Therapeutics, Inc. SEC Filing (Jul 20, 2026)

Market Reaction

Balanced read

61/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 76/100 classification
One-week reaction -3.8% Price reacting lower
Trend fit Trend active -35.1% over four weeks
Fair value -91.7% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 7
Neutral 25
Negative 13

Relevance

Why the article matched

Direct first
Direct company coverage 36
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 12
Market source 6
TradingView 5
Moomoo 3
TradingKey 3
Simply Wall Street 2
Investing.com South Africa 2
GlobeNewswire 2

Event Lens

What the news is about

Classified themes
Market update 19
Earnings 15
Deals and strategy 4
Balance sheet 4
Regulatory and legal 3

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-45 of 45
AlphaStreet Direct company coverage

Indaptus Therapeutics Releases Q1 2026 Financial Results

Indaptus Therapeutics, Inc. reported its Q1 2026 financial results, showing a significantly narrower loss of $0.23 per share, an improvement from $9.11 in the prior year. The clinical biotechnology company, trading as INDP, posted a net loss of $2.5M as it continues to advance it

Tone
Positive 70/100
Event
Earnings
Published
16 May 2026 07:10
Source
AlphaStreet
Stock Titan Direct company coverage

Indaptus Therapeutics (NASDAQ: INDP) cuts R&D, warns on cash runway

Indaptus Therapeutics (INDP) reported a Q1 2026 net loss of $2.54 million, an improvement from the previous year, largely due to a significant reduction in R&D spending as clinical activity was wound down. The company's cash and cash equivalents dwindled to $1.50 million, and it

Tone
Negative 13/100
Event
Balance sheet
Published
16 May 2026 06:39
Source
Stock Titan
Minichart Direct company coverage

Indaptus Therapeutics, Inc. Reports Substantial Doubt About Going Concern and Highlights Key Risks in Q1 2026 10-Q Filing

Indaptus Therapeutics, Inc. has reported a net loss of $2.54 million for Q1 2026 and an accumulated deficit of $83.83 million, leading to a substantial doubt about its ability to continue as a going concern. The company's stockholders' equity decreased significantly, and it antic

Tone
Negative 8/100
Event
Balance sheet
Published
16 May 2026 05:39
Source
Minichart